BOUL Stock Overview
Develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Boule Diagnostics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 8.88 |
| 52 Week High | SEK 12.62 |
| 52 Week Low | SEK 6.50 |
| Beta | 0.46 |
| 1 Month Change | 20.33% |
| 3 Month Change | 2.78% |
| 1 Year Change | -12.94% |
| 3 Year Change | -81.31% |
| 5 Year Change | -87.22% |
| Change since IPO | -24.26% |
Recent News & Updates
Improved Revenues Required Before Boule Diagnostics AB (publ) (STO:BOUL) Stock's 26% Jump Looks Justified
Dec 03
Does Boule Diagnostics (STO:BOUL) Have A Healthy Balance Sheet?
Oct 10Recent updates
Improved Revenues Required Before Boule Diagnostics AB (publ) (STO:BOUL) Stock's 26% Jump Looks Justified
Dec 03Does Boule Diagnostics (STO:BOUL) Have A Healthy Balance Sheet?
Oct 10Boule Diagnostics AB (publ) Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
Jul 25Capital Allocation Trends At Boule Diagnostics (STO:BOUL) Aren't Ideal
Jul 24Sentiment Still Eluding Boule Diagnostics AB (publ) (STO:BOUL)
Jun 06Results: Boule Diagnostics AB (publ) Exceeded Expectations And The Consensus Has Updated Its Estimates
May 10Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Mar 20Here's What Analysts Are Forecasting For Boule Diagnostics AB (publ) (STO:BOUL) After Its Yearly Results
Feb 09Boule Diagnostics AB (publ) (STO:BOUL) Screens Well But There Might Be A Catch
Dec 30Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Jul 25Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 49% Below Their Intrinsic Value Estimate
May 26Boule Diagnostics' (STO:BOUL) Solid Profits Have Weak Fundamentals
Jul 26Returns On Capital Signal Tricky Times Ahead For Boule Diagnostics (STO:BOUL)
Jul 19We Think Boule Diagnostics (STO:BOUL) Can Stay On Top Of Its Debt
Mar 06Investors Could Be Concerned With Boule Diagnostics' (STO:BOUL) Returns On Capital
Feb 03The Returns At Boule Diagnostics (STO:BOUL) Aren't Growing
Apr 29Should You Investigate Boule Diagnostics AB (publ) (STO:BOUL) At kr67.70?
Apr 09Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Mar 25Consider This Before Buying Boule Diagnostics AB (publ) (STO:BOUL) For The 1.0% Dividend
Mar 07Is Boule Diagnostics' (STO:BOUL) 210% Share Price Increase Well Justified?
Feb 17
These 4 Measures Indicate That Boule Diagnostics (STO:BOUL) Is Using Debt Extensively
Jan 30Is Boule Diagnostics AB (publ)'s (STO:BOUL) Shareholder Ownership Skewed Towards Insiders?
Jan 14How Many Boule Diagnostics AB (publ) (STO:BOUL) Shares Did Insiders Buy, In The Last Year?
Dec 28Boule Diagnostics AB (publ) (STO:BOUL) Shares Could Be 47% Below Their Intrinsic Value Estimate
Dec 10What Do The Returns On Capital At Boule Diagnostics (STO:BOUL) Tell Us?
Nov 22Shareholder Returns
| BOUL | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 3.3% | 0.4% | -2.7% |
| 1Y | -12.9% | -8.1% | 4.6% |
Return vs Industry: BOUL underperformed the Swedish Medical Equipment industry which returned -8.1% over the past year.
Return vs Market: BOUL underperformed the Swedish Market which returned 4.6% over the past year.
Price Volatility
| BOUL volatility | |
|---|---|
| BOUL Average Weekly Movement | 9.6% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: BOUL's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: BOUL's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1956 | 200 | Torben Nielsen | www.boule.com |
Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics companies.
Boule Diagnostics AB (publ) Fundamentals Summary
| BOUL fundamental statistics | |
|---|---|
| Market cap | SEK 344.84m |
| Earnings (TTM) | -SEK 212.52m |
| Revenue (TTM) | SEK 563.33m |
0.6x
P/S Ratio-1.6x
P/E RatioIs BOUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOUL income statement (TTM) | |
|---|---|
| Revenue | SEK 563.33m |
| Cost of Revenue | SEK 309.02m |
| Gross Profit | SEK 254.31m |
| Other Expenses | SEK 466.84m |
| Earnings | -SEK 212.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 11, 2025
| Earnings per share (EPS) | -5.47 |
| Gross Margin | 45.14% |
| Net Profit Margin | -37.73% |
| Debt/Equity Ratio | 64.3% |
How did BOUL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:42 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Boule Diagnostics AB (publ) is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jakob Lembke | ABG Sundal Collier Sponsored |
| null null | ABG Sundal Collier Sponsored |
| Christian Lee | Pareto Securities |